Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Tech entrepreneur and longevity advocate Bryan Johnson has discontinued his use of rapamycin, a controversial anti-ageing ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat ...

neuroscience leader with the drug’s manufacturer, Johnson & Johnson, said in a news release. “For too long, health care providers have had few options to offer patients much-needed symptom ...

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...